Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neratinib in Patients With HER2+ Breast Cancer: a Multi-centric, Multi-national, Prospective, Longitudinal, Non-interventional Study in Germany, Austria and Switzerland

NCT04388384 is registered in ClinicalTrials.gov with Pierre Fabre Pharma GmbH as lead sponsor.

NCT NCT04388384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04388384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neratinib in Patients With HER2+ Breast Cancer: a Multi-centric, Multi-national, Prospective, Longitudinal, Non-interventional Study in Germany, Austria and Switzerland
Lead sponsor
Pierre Fabre Pharma GmbH
Phase
Observational
Overall status
Completed
Start date
July 2, 2020
Completion date
September 5, 2024
Enrollment
304 (actual)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm